Showing 241-250 of 9109 results for "".
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto other JAK subtypes. The…
- Azitra Adds Barbara Ryan and John Schroer to Board of Directorshttps://practicaldermatology.com/news/azitra-adds-barbara-ryan-and-john-schroer-to-board-of-directors/2461876/Barbara Ryan and John Schroer joined Azitra, Inc.’s board of directors. "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets," says Francisco Salva, Presiden…
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an End of Phase-2 meeting. …
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic device offering a one-t…
- Fall Clinical PAs & NP Update: Castle's DecisionDx-SCC Can Identify Tumors Likely to Spread in Low-Risk CSCChttps://practicaldermatology.com/news/fall-clinical-pas-np-update/2461778/Castle Biosciences, Inc.’s DecisionDx-SCC test can identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging, according to research presented at the the 2023 Fall Clinical Dermatology Conference for PAs & NPs. DecisionDx-SCC is …
- Rare Skin Disease Update: Abeona's EB-101 Performs Well in a Phase 3 study of RDEBhttps://practicaldermatology.com/news/rare-skin-disease-update-abeonas-eb-101-performs-well-in-a-phase-3-study-of-rdeb/2461715/Abeona Therapeutics Inc.’s investigational EB-101 performed well in a Phase 3 study of recessive dystrophic epidermolysis bullosa (RDEB). Both co-primary endpoints were met, with the majority (81.4%) of randomized EB-101–treated wounds demonstrating ≥50% healing compared with 16.3% of untreated co…
- DermaSensor’s Skin Cancer Device May Help Primary Care Providers Spot Skin Cancerhttps://practicaldermatology.com/news/dermasensors-skin-cancer-device-may-help-internists-spot-skin-cancer/2461703/DermaSensor Inc.’s novel Elastic Scattering Spectroscopy (ESS) device can help primary care physician's spot skin cancers, according to two new studies presented at the Society of Teachers of Family Medicine 2023 annual meeting. The DermaSensor device is currently CE Marked and is available for sa…
- Skin Cancer Foundation Hits the Road: Destination Healthy Skin Program Kicks Off on May 6, 2023https://practicaldermatology.com/news/skin-cancer-foundation-hits-the-road-destination-healthy-skin-program-kicks-off-on-may-6-2023/2461669/The Skin Cancer Foundation will launch its annual mobile education and screening program, Destination Healthy Skin, on Saturday, May 6, in Greenwich, Connecticut. The program educates the public about the importance of skin cancer early detection and effective sun protection. Inside the Destinati…
- The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Launch Digital Online Free Image Galleryhttps://practicaldermatology.com/news/the-full-spectrum-of-dermatology-a-diverse-and-inclusive-atlas-launch-digital-online-free-image-gallery/2461500/“The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas” is launching a digital online free image gallery. The online image gallery provides more than 800 images of 110 commonly diagnosed dermatologic conditions in an array of skin tones, and compliments the print atlas which was first …
- CeraVe Establishes Fund at Howard University to Address Lack of Diversity in Skincare Clinical Researchhttps://practicaldermatology.com/news/cerave-establishes-fund-at-howard-university-to-address-lack-of-diversity-in-skincare-clinical-research/2461435/To help close the existing racial inequity gap in dermatological research, CeraVe is establishing a fund at Howard University to help its faculty further their expertise and build the infrastructure needed to conduct clinical trials with a focus on skin of color. Located in Washington D.C, Howard …